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Abstract
Summary In this study, we demonstrate a high prevalence of
secondary factors in patients with a recent fracture indepen-
dently of bone mineral density (BMD). Our results suggest
that patients with a recent fracture should be screened for
secondary factors for bone fragility regardless of BMD values.
Introduction Secondary factors for bone fragility are common
in patients with osteoporosis who have sustained a fracture.
The majority of fragility fractures occurs, however, in patients
with osteopenia, and it is not known whether secondary fac-
tors may contribute to fracture risk in these patients or in those
with normal BMD.
Methods Prospective cohort study evaluating the prevalence
of secondary factors for bone fragility in consecutive patients
referred to our fracture liaison service from June 2012 to June
2014 after a recent fracture.
Results Seven hundred nine patients were included, 201
(28 %) with osteoporosis, 391 (55 %) with osteopenia and
117 (17%)with normal BMD.Mean age was 66.0±9.8 years,
504 (73 %) were women and 390 (57 %) had one or more
underlying secondary factor. Evaluation of clinical risk factors
using fracture risk assessment tool (FRAX) identified 38 % of
patients with ≥1 secondary factor including smoking (18 %),
excessive alcohol use (12 %), glucocorticoid use (12 %) and
rheumatoid arthritis (3 %). Laboratory investigations revealed
chronic kidney disease in 13 %, monoclonal gammopathy
also in 13 % and primary or secondary hyperparathyroidism
in 1 and 6%, respectively. Secondary factors for bone fragility
were equally prevalent in patients with osteoporosis,
osteopenia or normal BMD.
Conclusions Our findings demonstrate a high prevalence of
secondary factors for bone fragility in patients who have
sustained a recent fracture, independently of BMD. The sig-
nificant number of documented factors, which were treatable,
suggest that patients who sustained a fracture should be
screened for secondary factors for bone fragility regardless
of BMD values to optimise secondary fracture prevention.
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Introduction
Osteoporotic fragility fractures are associated with increased
morbidity and mortality and growing personal, societal and
economic burdens [1–4]. The presence of a fragility fracture
has also been shown to significantly increase the risk of future
fractures [5, 6]. Over the past decade, fracture liaison services
(FLS) have been globally implemented to improve the identi-
fication and treatment of patients at risk for a new fracture in a
cost-effective approach [7, 8]. Patients who sustain a fracture
and who have osteoporosis are offered treatment with bone-
modifying agents, but a significant number of patients who
sustain a fracture have bone mineral density (BMD) in the
osteopenia range [9, 10], and in the Netherlands, these are
not generally screened for secondary factors for bone fragility
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and are not routinely offered anti-osteoporosis treatment [11,
12].
Secondary factors for bone fragility are common in patients
with osteoporosis and a fragility fracture [13–15], but data on
the prevalence of these factors in patients with osteopenia or
normal BMD and a fragility fracture are scarce [13, 15].
Postmenopausal women with osteopenia and fragility frac-
tures have been shown to have poor bone microarchitecture
and altered material properties of the bone, which may also be
influenced by secondary factors for bone fragility [16–19]. To
assess the potential contribution of secondary factors for bone
fragility to fracture risk, we set out to evaluate the prevalence
of these factors in a cohort of patients who had recently
sustained a fracture and who were referred to the FLS for
further investigation and management.
Patients and methods
Study design
In this prospective cohort study, all patients ≥50 years old with
a recent fracture, who were referred to the FLS of the Leiden
UniversityMedical Center from June 2012 to June 2014, were
screened for secondary factors for bone fragility.
Patients
Patients were informed of their referral to the FLS during their
follow-up visit for primary fracture care at the outpatient
clinics of the departments of traumatology and orthopaedic
surgery. Excluded from the study were patients with an isolat-
ed fracture of the skull, hands or feet, patients with patholog-
ical fractures or those with fractures resulting from failure of
prosthesis. Patients who had undergone screening for osteo-
porosis in another hospital were also not included in the study.
Patients with impaired cognitive function or poor general con-
dition were also excluded from the study; Fig. 1.
Study parameters
The following data were collected in all patients: age, gender,
height and weight (from which body mass index (BMI) was
calculated), a full medical history including detailed fracture
history, family history of osteoporosis, dietary calcium intake,
age at menopause (early menopause was defined as meno-
pause at age ≤45 years), parental history of hip fracture, alco-
hol use, corticosteroid use, smoking, current use of medica-
tion, including vitamin D supplementation, past or present use
of hormone replacement therapy and past or present use of
bone-modifying agents. The 10-year probabilities for a major
osteoporotic fracture and for a hip fracture were calculated
using the World Health Organization (WHO) fracture risk
assessment tool (FRAX) algorithm using reference values
for the Dutch population [20]. The 10-year fracture probabil-
ities were calculated with and without inclusion of values for
femoral neck BMD.
Bone mineral density
Bone mineral density was measured at the lumbar spine (L1–
L4) and at the left and right femoral neck by dual-energy X-ray
absorptiometry (DXA) using Hologic QDR Discovery A
(Hologic, Bedford, MA, USA). T scores were calculated using
NHANES III reference values compatible with reference values
for the Dutch population. The World Health Organization
criteria were used to define osteoporosis, osteopenia and normal
BMD.Average values of right and left femoral neck BMDwere
used in the analysis of data, except when both sides could not be
measured due to the presence of a prosthesis.
Laboratory investigations
Serum was measured for calcium, albumin, inorganic phos-
phate, alkaline phosphatase, potassium, sodium, ureum, cre-
atinine, TSH, PTH, 25-OH vitamin D and P1NP. Vitamin D
deficiency was defined as serum levels of 25-OH vitamin D
<50 nmol/L. Renal function was assessed by calculating the
estimated glomerular filtration rate (eGFR) using the modifi-
cation of diet in renal disease (MDRD) formula. Stages of
chronic kidney disease were defined as I to V according to
Fig 1 Flowchart of inclusion of patients in the study after presenting to
the Emergency Room of the Leiden University Medical Center with a
recent fracture. ER emergency room, FLS fracture liaison service, GP
general practitioner
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the classification of the National Kidney Foundation KDOQI
[21]. Primary hyperparathyroidism was diagnosed by hyper-
calcemia (albumin corrected calcium >2.55 mmol/L) in the
presence of an inappropriately normal or elevated PTH level
(PTH > 8.0 pmol/L), in the absence of thiazide use.
Hyperthyroidism was diagnosed by a repeated TSH level
<0.300 mU/L in the presence of a free T4 (fT4) level >22.0
pmol/L and subclinical hyperthyroidism by a TSH level
<0.300 mU/L in the presence of a fT4 level between 10.0–
24.0 pmol/L, without use of interfering medication.
Hypogonadism was screened for in men <70 years of age
and was diagnosed by a total testosterone level of <8 nmol/L
in a morning sample. Screening for a monoclonal
gammopathy using immunofixation was undertaken at the
discretion of the treating physician, mostly in case of unex-
pected osteoporosis and/or multiple fractures, also in the pres-
ence of osteopenia. Monoclonal gammopathy of undeter-
mined significance (MGUS) was defined by the presence of
M-protein in serum at a concentration of up to 10 g/L, with no
signs of organ damage in the form of anaemia, hypercalcemia,
kidney insufficiency or bone lesions [22].
Statistical analysis
All analyses were performed using the SPSS software for
Windows (Version 20.0; SPSS Inc., Chicago, IL, USA).
Between-group differences in baseline characteristics were
assessed using ANOVA, a Chi-square test or a Kruskall
Wallis test. The prevalence of secondary factors for bone fra-
gility according to the recently sustained fracture type was
assessed using a Chi-square test. Pearson correlation coeffi-
cients were used to express correlations between the 10-year
FRAX probability calculated with and without femoral neck
BMD values (after logarithmic transformation), lumbar spine
and mean femoral neck BMD, and the number of secondary
factors for bone fragility. Partial correlation coefficients were
calculated to assess the correlation between number of sec-
ondary factors and lumbar spine and mean femoral neck BMD
after adjusting for age, gender and BMI. Multivariate logistic
regression analysis was used to assess the contribution of
BMD: normal, osteopenia and osteoporosis (variable) to the
prevalence of secondary factors for bone fragility (outcome),
adjusted for age, gender and BMI.
Differences were considered to be significant at p<0.05.
Results
In the 2-year study period, 1562 patients presented to the
emergency room of the Leiden University Medical Center
with a recent fracture. Seven hundred six patients were not
referred to the fracture liaison service for a variety of reasons
detailed in Fig. 1. Compared to this group, the 856 patients
who were referred were younger (68.6±11.2 years vs. 72.2
± 12.9 years, p< 0.001), predominantly female (71 % vs.
69 %) and had sustained less hip fractures (hip fracture/
vertebral fracture/non-hip non-vertebral fracture 9/6/85 %
vs. 22/8/70 %; p<0.001). There was no significant difference
in the number of female patients who were referred to the FLS
or not, p=0.229.
Of these 856 patients referred, 709 agreed to be further
investigated for the presence of secondary factors for bone
fragility and were included in the study. These were 196
men and 513 women, with a mean age of 67.1±10.2 years
(range 50.0–94.0 years). Sixty-one (9%) had a hip fracture, 40
(6 %) a clinical vertebral fracture and 608 (86 %) a non-hip/
non-vertebral (NH/NV) fracture.
Two hundred one patients (28 %) had osteoporosis, 391
(55 %) had osteopenia and 117 (17 %) had normal bone min-
eral density (BMD). Data on FRAX clinical risk factors for
fracture and/or laboratory data were incomplete in 23 patients,
so that 686 patients were included in the final analysis, 385 of
whom had osteopenia and 102 normal BMD.
After stratification of patients according to BMD, there were
significant differences in mean age (64.7±9.9 vs. 66.0±9.8 vs.
70.5±10.2 years, p<0.001), gender distribution (34 vs. 29 vs.
17%male patients, p=0.001) andBMI (28.2±5.1 vs. 26.7±4.1
vs. 24.3±3.8 kg/m2, p<0.001) between groups of patients with
respectively normal BMD, osteopenia and osteoporosis. There
was no difference in biochemical parameters, number of patients
with a previous fracture or with a history of parental hip fracture
between the three BMD groups; Table 1.
The majority of patients had a non-hip/non-vertebral (NH/
NV) fracture [n=586 (85 %)], 60 patients (9 %) had a hip
fracture and 40 patients (6 %) had a clinical vertebral fracture.
The most prevalent NH/NV fracture was a wrist fracture
[n=221 (32 %)] followed by a fracture of the proximal hu-
merus [n=91 (13 %)] and of the ankle [n=79 (12 %)]. Forty
patients (67 %) with a hip fracture had a secondary factor for
bone fragility, 28 patients (70 %) with a vertebral fracture and
322 patients (55 %) with a NH/NV fracture; p=0.049.
A similar distribution of fractures was observed in patients
with normal BMD: 6 (6 %) hip fracture, 4 (4 %) clinical
vertebral fracture and 92 (90 %) NH/NV fracture; osteopenia:
33 (9 %) hip fracture, 19 (5 %) vertebral fracture and 333
(86 %) NH/NV fracture; and in patients with osteoporosis:
21 (11 %) hip fracture, 17 (9 %) vertebral fracture and 161
(81 %) NH/NV fracture.
Secondary factors identified by clinical risk factors using
FRAX
In patients with normal BMD, 13 patients (13 %) used ≥3
units of alcohol a day, 11 (11 %) were currently using or had
previously used glucocorticoids, 15 (16 %) were active
smokers and 3 (3 %) had rheumatoid arthritis; Table 2. Eight
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patients (9 %) had a history of parental hip fracture, and 41
(40 %) had sustained one or more previous fractures. The
median FRAX 10-year fracture probability was 5.2 % for a
major osteoporotic fracture and 0.5 % for a hip fracture, and
was 7.3 % and 2.2 %, respectively without inclusion of fem-
oral neck BMD in the calculation.
In patients with osteopenia, 44 patients (11%) usedmore than
3 units of alcohol per day, 42 (11 %) were currently using or had
previously used glucocorticoids, 64 (17 %) were active smokers
and 11 (3 %) had rheumatoid arthritis; Table 2. Fifty patients
(13 %) had at least one parent with a history of a hip fracture,
and 163 patients (42 %) had sustained a previous fracture.
Table 1 Characteristics of

















BMI (kg/m2) 28.2 ± 5.1 26.7 ± 4.1 24.3 ± 3.8 <0.001
Previous facture (%) 41 (40) 163 (42) 83 (42) 0.918
Parental hip fracture (%) 10 (10) 50 (13) 28 (14) 0.560
FRAX score major fracture 5.2 ± 0.6 8.9 ± 0.3 17.0 ± 0.7 <0.001
FRAX score hip fracture 0.5 ± 0.3 2.2 ± 0.2 7.3 ± 0.6 <0.001
Laboratory data:
Calcium (mmol/L) 2.40 ± 0.12 2.41 ± 0.12 2.41± 0.11 0.648
Creatinine (μmol/L) 74.4 ± 15.3 74.7 ± 19.1 72.3 ± 26.4 0.422
PTH (pmol/L) 4.0 ± 2.4 4.4 ± 2.8 4.9 ± 4.2 0.111
25-OH D (nmol/L) 62.7 ± 36.6 57.5 ± 28.2 58.4 ± 30.5 0.677
DXA measurements:
LS BMD (g/cm2) 1.11 ± 0.12 0.95 ± 0.12 0.80± 0.14 <0.001
T score LS 0.5 ± 1.0 −1.0 ± 1.0 −2.3 ± 1.2 <0.001
FN BMD (g/cm2) 0.86 ± 0.10 0.70 ± 0.07 0.58± 0.08 <0.001
T score FN −0.1 ± 0.7 −1.5 ± 0.5 −2.5 ± 0.6 <0.001
BMI body mass index, DXA dual-energy X-ray absorptiometry, LS lumbar spine, FN femoral neck, BMD bone
mineral density













FRAX clinical risk factors:
Smoking (%) 42 (23) 80 (16) 15 (16) 64 (17) 43 (22) 122 (18)
Use of >3 IU alcohol (%) 30 (17) 49 (10) 13 (13) 44 (11) 22 (11) 79 (12)
Glucocorticoids (%) 14 (8) 66 (13) 11 (11) 42 (11) 27 (14) 80 (12)
Rheumatoid arthritis (%) 2 (1) 20 (4) 3 (3) 11 (3) 8 (4) 22 (3)
Early menopause (%) – 96 (19) 13 (13) 45 (12) 38 (19) 96 (14)
Laboratory-based factors
Chronic kidney disease (%) 15 (8) 77 (15) 10 (10) 53 (14) 29 (15) 92 (13)
MGUS (%) 25 (14) 65 (13) 5 (5) 46 (12) 39 (20) 90 (13)
1° hyperparathyroidism (%) – 7 (1) 1 (1) 4 (1) 2 (1) 7 (1)
2° hyperparathyroidism (%) 7 (4) 35 (7) 3 (3) 25 (7) 14 (7) 42 (6)
Hyperthyroidism (%) 1 (1) 12 (2) 1 (1) 7 (2) 5 (3) 13 (2)
Hypogonadism (%) 8 (4) – 1 (1) 6 (2) 1 (1) 8 (1)
Patients with >1 factor (%) 93 (51) 297 (59) 48 (47) 219 (57) 123 (62) 390 (57)
IU international unit
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The median 10-year fracture probability as calculated by
FRAX was 8.9 % for a major osteoporotic fracture and 2.2 %
for a hip fracture. Without inclusion of femoral neck BMD in
the calculation, the median 10-year fracture probability was
9.4 % for a major osteoporotic fracture and 2.8 % for a hip
fracture.
In patients with osteoporosis, 22 patients (11 %) used ≥3
units of alcohol a day, 27 (14 %) were currently using or had
previously used glucocorticoids, 43 (22 %) were active
smokers and 8 (4 %) had rheumatoid arthritis; Table 2.
Twenty-eight patients (14 %) had a history of parental hip
fracture, and 83 (42 %) had sustained one or more previous
fractures.
The median 10-year fracture probability with inclusion of
femoral neck BMDwas 17% for a major osteoporotic fracture
and 7.3 % for a hip fracture, and respectively 16 and 6.2 %
without inclusion of femoral neck BMD in the calculation.
There was a significant difference in the 10-year FRAX
probability for fracture between patients with normal BMD,
osteopenia or osteoporosis, with or without inclusion of fem-
oral neck BMD measurements; Table 1. A similar number of
patients with normal BMD, osteopenia or osteoporosis had an
underlying factor for bone fragility as identified by clinical
risk factors for fracture using FRAX (41 patients with normal
BMD (40 %) vs. 164 patients with osteopenia (43 %) vs. 95
patients with osteoporosis (48 %); p=0.381). There was no
difference in the prevalence of any individual clinical risk
factor studied between the groups; Fig. 2a.
There was a significant difference in the 10-year FRAX
probability for fracture calculated with BMD values between
patients with ≥1 secondary factor and patients without (12.0
vs. 8.5 %; p<0.001), and in the 10-year FRAX probability
without BMD values (13.0 vs. 8.3 %; p<0.001). Interestingly,
there was a significant relationship between the cumulative
number of factors for bone fragility and the 10-year FRAX
probability (r=0.336, p<0.001), and in the 10-year FRAX
probability calculated without BMD values (r = 0.359,
p<0.001). After stratification for BMD status, this relation-
ship remained for normal BMD (r= 0.286, p= 0.004 for
FRAX with BMD and r=0.456, p<0.001 for FRAX without
BMD), osteopenia (r=0.313, p<0.001 for FRAX with BMD
and r=0.311, p<0.001 for FRAX without BMD) and osteo-
porosis (r = 0.361, p < 0.001 for FRAX with BMD and
r=0.346, p<0.001 for FRAX without BMD).
Secondary factors identified by laboratory investigations
Laboratory investigations identified an underlying factor for
bone fragility in 18 (18 %) of patients with normal BMD, in
112 (29 %) of patients with osteopenia and in 69 (35 %) of
patients with osteoporosis.
In patients with normal BMD, chronic kidney disease was
diagnosed in ten patients (10 %), all of whom had chronic
kidney disease (CKD) stage III. One patient (1%) had primary
hyperparathyroidism, and three (3 %) had secondary hyper-
parathyroidism (associated with low 25-OH vitamin D levels
in two, and combined vitamin D deficiency and renal failure in
one). One patient (1%) had hyperthyroidism, one male patient
had hypogonadism and five (5 %) patients were diagnosed
with MGUS.
In patients with osteopenia, chronic kidney disease was
diagnosed in 53 patients (14 %), of whom 49 had stage III
CKD and 4 had stage IV CKD. Four patients (1 %) had pri-
mary hyperparathyroidism and 25 (7 %) had secondary hy-
perparathyroidism (associated with low 25-OH vitamin D
levels in 15, and combined vitamin D deficiency and renal
failure in 8). Seven patients (2 %) had hyperthyroidism (5
subclinical), 6 men had hypogonadism and 46 (12 %) patients
were diagnosed with MGUS.
In patients with osteoporosis, chronic kidney disease was
diagnosed in 29 patients (15 %), of whom 26 had stage III







Prevalence of secondary factors for bone fragility

















Fig. 2 a No significant difference in the prevalence of underlying
secondary factors for bone fragility between patients with normal BMD
(white bars) osteopenia (grey bars) or osteoporosis (black bars) using
FRAX. RA rheumatoid arthritis, EM early menopause. b Prevalence of
underlying secondary factors for bone fragility by laboratory
investigations in patients with normal BMD (white bars), osteopenia
(grey bars), and osteoporosis (black bars). Significantly different
prevalence of MGUS in patients between the groups. CKD chronic
kidney disease, MGUS monoclonal gammopathy of undetermined
significance, 1° HPT primary hyperparathyroidism, 2° HPT secondary
hyperparathyroidism, HG hypogonadism, HT hyperthyroidism.
*p= 0.001
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CKD and 3 had stage IV CKD. Two patients (1 %) had pri-
mary hyperparathyroidism, and 14 had secondary hyperpara-
thyroidism (associated with low 25-OH vitamin D levels in 7,
and combined vitamin D deficiency and renal failure in 7).
Five patients (3 %) had hyperthyroidism (2 subclinical), 1
male patient had hypogonadism and 39 (20 %) patients were
diagnosed with MGUS.
All underlying factors for bone fragility identified by
laboratory investigations were equally prevalent in pa-
tients with normal BMD, osteopenia or osteoporosis,
except for MGUS (5 vs. 12 vs. 20 %; p = 0.001);
Fig. 2b. One patient with osteoporosis was diagnosed
as having multiple myeloma.
The odds of a patient with osteopenia having an MGUS
were 2.71 times higher than those of a patient with normal
BMD, and the odds of a patient with osteoporosis having an
MGUS were 4.81 times higher than those of a patient with
normal BMD. There was no association between BMD and
the odds for any other factor for bone fragility; Table 3.
Relationship between number of secondary factors
for bone fragility and BMD measurements
Three hundred ninety patients (57 %) had one or more under-
lying secondary factor for bone fragility. The majority of pa-
tients (n=205 [30 %]) had one underlying factor, 122 patients
(18 %) had two and 63 (9 %) had three or more factors; 38 %
of all observed underlying factors were identified by labora-
tory investigations, and 41 % of all factors were reversible.
There was an inverse relationship between the number of un-
derlying factors for bone fragility per patient and mean femo-
ral neck BMD values (r=−0.215, p<0.001), which persisted
after adjusting for age, gender and BMI (r = −0.192,
p<0.001).
In patients with normal BMD, 29 patients (28 %) had
one underlying factor, 13 patients (13 %) had two factors
and 6 (6 %) had three or more factors. In patients with
osteopenia, the majority of patients (n=122 [32 %]) had
one underlying factor, 69 patients (18 %) had two and 28
(7 %) had three or more factors. In patients with osteopo-
rosis, 54 patients (27 %) had one secondary factor for
bone fragility, 40 patients (20 %) had two factors and
29 (15 %) had three or more factors.
Vitamin D deficiency
Vitamin D deficiency was prevalent in 292 (43 %) of the 686
patients, of whom 97 had serum vitamin D levels <25 nmol/L.
Vitamin D deficiency was documented in 43 patients (42 %)
with normal BMD, in 166 patients (43 %) with osteopenia and
in 83 patients (42 %) patients with osteoporosis.
Discussion
Our data from this study demonstrate that 57 % of patients,
who recently sustained a fracture and who were subsequently
referred to our fracture liaison service, had one or more un-
derlying secondary factor for bone fragility. Interestingly,
these secondary factors were equally prevalent in our cohort
of patients with a recent fracture whether they had normal
bone mineral density (BMD), osteopenia or osteoporosis (47
vs. 57 vs. 62 % respectively; p=0.05). Our data also show a
significant inverse relationship between the number of under-
lying factors for bone fragility and femoral neck BMD. The
most prevalent underlying factors for bone fragility were
smoking (18 %), chronic kidney disease (13 %) and MGUS
(13 %). Of clinical relevance is that 41 % of all documented
secondary factors for bone fragility were reversible (hyperthy-
roidism, primary and secondary hyperparathyroidism,
hypogonadism in men or potentially reversible such as exces-
sive alcohol use and smoking). This may hold significant clin-
ical implications in the management of these patients as
Table 3 Odds ratio for factors for increased bone fragility in patients
with osteoporosis and osteopenia, compared with patients with normal
BMD















































For every risk factor listed, odds ratio refers to patients with osteoporosis
at the top line and to patients with osteopenia at the second line. Patients
with normal BMD are used as reference
IU internal unit, MGUS monoclonal gammopathy of undetermined
significance
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reversal of these factors may be associated with an improve-
ment in bone strength, thus contributing in time to a decrease
in bone fragility. In addition, 43 % had serum levels of 25-OH
vitamin D <50 nmol/L.
The prevalence of secondary factors for bone fragility has
been previously reported in patients with a recent fracture [13,
15]. Although the majority of previously published data stud-
ied the prevalence of underlying factors for bone fragility in
patients with osteoporosis [13–15, 23–27], our findings sug-
gest a similar prevalence of these factors regardless of BMD
measurements after a recent fracture. A novel approach we
pursued in this analysis was to compare the prevalence of
underlying factors for bone fragility between the groups of
patients with normal BMD, osteopenia or with osteoporosis
in our cohort of 686 patients aged ≥50 years who had
sustained a recent fracture.
As expected, the FRAX 10-year probability for a fracture
was significantly different in patients with normal BMD,
osteopenia or osteoporosis. This was also the case when fem-
oral neck BMD was not used in the calculation of the FRAX.
Our data also demonstrate that patients with one or more sec-
ondary factor for bone fragility had a higher 10-year FRAX
fracture probability compared to patients with no documented
secondary factor(s). Interestingly, there was a positive rela-
tionship between the cumulative number of secondary factors
for bone fragility and FRAX independently of BMD status,
which suggests that FRAX may not fully capture the contri-
bution of the cumulative effect of these factors on fracture risk.
Our study has strengths as well as limitations. One of its
main strengths is that all fracture patients were identified at
source at the outpatient clinics of the departments of
traumatology and orthopaedic surgery by a dedicated fracture
nurse from our FLS resulting in the successful referral of
>50 % patients to our FLS for screening for osteoporosis.
Over the last decade, there has been an increasing drive to
develop and implement FLSs on an international scale for
the secondary prevention of fractures [28]. These FLSs ensure
that future fracture risk is assessed in all patients who have
sustained a recent fracture, including the risk of falling [29].
These FLSs also secure that treatment with bone-modifying
agents is initiated if and when required. Previous studies dem-
onstrated that the implementation of an FLS was cost-
effective and effectively reduced mortality and the incidence
of subsequent non-vertebral fractures [8, 30].
A further strength of the study is the availability of data on
clinical risk factors using FRAX, of BMD data and of labora-
tory data on the most common secondary factors for bone
fragility. A main limitation of the study is that due to regional
hospital policy, the majority of patients who presented to our
emergency room with a hip fracture were transferred to other
hospitals in the region for primary fracture care, which could
have influenced patient characteristics, especially age. The
limited screening for monoclonal gammopathy of
undetermined significance (MGUS) may also be considered
as a limitation of our study, as data may have been confounded
by the bias of the treating physician’s decision to screen pa-
tients at higher risk for underlying secondary factors for bone
fragility. However, this would have led to an underestimate
rather than an overestimate of the prevalence of anMGUS. LS
BMD measurements were not adjusted for the presence of
degenerative changes, which might explain the absence of a
relationship between the number of underlying factors for
bone fragility and LS BMD. However, we also found no cor-
relation between the number of underlying factors and LS
BMD in patients stratified by age groups (data not shown).
Our data, demonstrating a high prevalence of secondary
factors for bone fragility, independently of BMD status, in a
cohort of patients who had sustained a recent fracture, hold
significant clinical implications in the management of these
patients, as nearly half of these factors were potentially revers-
ible. Our findings suggest that screening for underlying sec-
ondary factors for bone fragility should be considered in the
setting of fracture liaison services, not only in patients with
osteoporosis but also in those with osteopenia or normal
BMD. Whether reversing secondary factors for bone fragility
would result in more optimal secondary prevention of frac-
tures remains to be established by long-term studies.
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